Shares of BioScrip Inc (NASDAQ:BIOS) have been assigned an average rating of “Hold” from the seven ratings firms that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $5.00.
Several equities research analysts have recently weighed in on BIOS shares. Canaccord Genuity reduced their price target on BioScrip from $5.00 to $3.50 and set a “buy” rating on the stock in a report on Monday, March 18th. Barrington Research reiterated a “buy” rating and issued a $4.00 price target on shares of BioScrip in a report on Friday, May 3rd. TheStreet downgraded BioScrip from a “c-” rating to a “d” rating in a report on Wednesday, April 3rd. Stephens downgraded BioScrip from an “overweight” rating to an “equal weight” rating and set a $2.51 price target on the stock. in a report on Monday, March 18th. Finally, BidaskClub upgraded BioScrip from a “sell” rating to a “hold” rating in a report on Thursday, May 9th.
Large investors have recently made changes to their positions in the stock. Maven Securities LTD bought a new position in BioScrip in the fourth quarter worth approximately $45,000. Caxton Associates LP bought a new position in BioScrip in the fourth quarter worth approximately $52,000. Virtu Financial LLC grew its stake in BioScrip by 60.6% in the fourth quarter. Virtu Financial LLC now owns 18,208 shares of the company’s stock worth $65,000 after purchasing an additional 6,868 shares in the last quarter. Federated Investors Inc. PA grew its stake in BioScrip by 254.6% in the first quarter. Federated Investors Inc. PA now owns 20,469 shares of the company’s stock worth $41,000 after purchasing an additional 14,697 shares in the last quarter. Finally, SG Americas Securities LLC bought a new position in BioScrip in the first quarter worth approximately $49,000. 78.98% of the stock is currently owned by institutional investors.
BioScrip (NASDAQ:BIOS) last issued its quarterly earnings results on Thursday, May 2nd. The company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.01. The business had revenue of $178.96 million during the quarter, compared to analysts’ expectations of $179.23 million. During the same quarter in the previous year, the company posted ($0.12) earnings per share. The company’s quarterly revenue was up 6.2% compared to the same quarter last year. Equities research analysts expect that BioScrip will post -0.23 earnings per share for the current fiscal year.
BioScrip, Inc provides infusion and home care management solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods.
Read More: Trading Options- What is a Strangle?
Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.